论文部分内容阅读
目的探讨贝那普利联合缬沙坦治疗糖尿病肾病患者的临床疗效。方法选取2014年11月至2016年11月辽阳市中心医院收治的66例糖尿病肾病患者作为研究对象,按随机数字表法将其分为对照组与观察组,各33例。对照组患者以贝那普利治疗,观察组患者以贝那普利联合缬沙坦治疗,比较两组患者的治疗效果。结果治疗后观察组患者收缩压、舒张压、24 h尿蛋白分别为(128±9)mm Hg、(78±5)mm Hg、(0.40±0.12)g,均明显低于对照组的(135±10)mm Hg、(86±6)mm Hg、(0.58±0.19)g,差异均有统计学意义(均P<0.05);两组患者治疗后空腹血糖、尿素氮、血肌酐、血钾水平及药物不良反应发生率差异均无统计学意义(均P>0.05)。结论贝那普利联合缬沙坦可促使糖尿病肾病患者血压水平及尿蛋白水平明显改善,且用药安全可靠。
Objective To investigate the clinical efficacy of benazepril combined with valsartan in the treatment of diabetic nephropathy. Methods Sixty-six patients with diabetic nephropathy admitted from Liaoyang Central Hospital from November 2014 to November 2016 were selected as study subjects, and divided into control group and observation group according to random number table method, with 33 cases in each group. The patients in the control group were treated with benazepril, the patients in the observation group were treated with benazepril and valsartan, and the treatment effect was compared between the two groups. Results After treatment, the systolic blood pressure, diastolic blood pressure and urinary protein in 24 h were (128 ± 9) mm Hg, (78 ± 5) mm Hg and (0.40 ± 0.12) g respectively in the observation group, which were significantly lower than those in the control group (P <0.05). After treatment, fasting blood glucose, blood urea nitrogen, serum creatinine, serum potassium There was no significant difference in the incidence of adverse reactions and adverse reactions (all P> 0.05). Conclusion The combination of benazepril and valsartan can promote the blood pressure and proteinuria of patients with diabetic nephropathy significantly improved, and the medication is safe and reliable.